Figure 2.
Distribution of attained comfortable tolerance level (CTL) stimulation intensities in ImpACT-24M (Implant for Augmentation of Cerebral Blood Flow Trial in Mild Strokes) and clinical efficacy dose-response curve (for favorable 3-month disability outcome) observed in ImpACT-24B trial (Implant for Augmentation of Cerebral Blood Flow Trial B). Blue bar histogram shows ImpACT-24M CTL stimulation intensities from 0-100% of electrode maximum in bin sizes of 5%. Solid green line shows odds ratios (OR) for favorable 3-month disability outcome at different stimulation intensities in the ImpACT-24B (and dotted lines show 95% CI).